Molecular profiling of XXXX using next generation sequencing.

@entity1 @entity984 @entity876 @entity818 @entity201 @entity1419 @entity8497 @entity817
@entity201 is a heterogeneous malignant process, which is further classified into @entity1419 ( @entity1419 ) and @entity201 ( @entity201 ). The poor prognosis of the disease is partly due to the lack of understanding of the disease mechanism. Multiple gene alterations identified by various molecular techniques have been described recently. As a result, multiple targeted therapies for @entity1419 and @entity201 are being developed. In this study, we identified and compared somatic mutations in @entity1419 and @entity201 @entity1 using next generation sequencing (NGS) (Ampliseq Cancer Hotspot Panel v2 and Ion Torrent 318v2 chips). Eleven of 16 samples passed internal quality control established for NGS testing. @entity1419 cases (n=3) showed @entity818 (33.3%) and @entity8497 (33.3%) mutations. Meanwhile, @entity876 (75%), @entity984 (50%), and @entity817 (12.5%) mutations were identified in @entity201 cases (n=8). Our study confirmed the molecular heterogeneity of @entity1419 and @entity201 using NGS. This information will be important for individual @entity1 as targeted therapies for @entity1419 and @entity201 become available in the future.
